Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Inobrodib - CellCentric

Next Previous
Drug Profile

Inobrodib - CellCentric

Alternative Names: CCS-1477

Latest Information Update: 04 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CellCentric
  • Class Antineoplastics; Fluorobenzenes; Imidazoles; Isoxazoles; Piperidines; Small molecules
  • Mechanism of Action P300-CBP transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours
  • No development reported Bladder cancer; Lung cancer; Malignant melanoma

Most Recent Events

  • 17 Aug 2026 Phase-III clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO)(NCT07772024)
  • 14 Jun 2026 Efficacy and adverse event data from phase II trial in Multiple myeloma presented at the 31st Congress of the European Haematology Association (EHA-2026)
  • 28 May 2026 No recent reports of development identified for preclinical development in Malignant-melanoma in United Kingdom (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top